Evidence map›Paper›PMID 28731042›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2017

Molecular alterations of coexisting thyroid papillary carcinoma and anaplastic carcinoma: identification of TERT mutation as an independent risk factor for transformation.

Naoki Oishi, Tetsuo Kondo, Aya Ebina, Yukiko Sato, Junko Akaishi, Rumi Hino, Noriko Yamamoto, Kunio Mochizuki, Tadao Nakazawa, Hiroshi Yokomichi and 3 more

Open access · hybridAbstract read
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 3 pooled it
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 3 syntheses or guidelines pooled it, 101 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer.Thyroid : official journal of the American Thyroid Association · 2021
    Guideline
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Role ofMolecular and clinical oncology · 2025
    Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Naoki OishiDepartment of Pathology, University of Yamanashi, Chuo, Yamanashi, Japan.ORCID 0000-0002-9365-1093
Tetsuo KondoDepartment of Pathology, University of Yamanashi, Chuo, Yamanashi, Japan.
Aya EbinaDivision of Head and Neck Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Yukiko SatoDivision of Pathology, Cancer Institute of Japanese Foundation for Cancer Research, Tokyo, Japan.
Junko AkaishiDepartment of Surgery, Ito Hospital, Tokyo, Japan.
Rumi HinoDivision of Pathology, Cancer Institute of Japanese Foundation for Cancer Research, Tokyo, Japan.
Noriko YamamotoDivision of Pathology, Cancer Institute of Japanese Foundation for Cancer Research, Tokyo, Japan.
Kunio MochizukiDepartment of Pathology, University of Yamanashi, Chuo, Yamanashi, Japan.
Tadao NakazawaDepartment of Pathology, University of Yamanashi, Chuo, Yamanashi, Japan.
Hiroshi YokomichiDepartment of Health Sciences, University of Yamanashi, Chuo, Yamanashi, Japan.ORCID 0000-0001-7369-155X
Koichi ItoDepartment of Surgery, Ito Hospital, Tokyo, Japan.
Yuichi IshikawaDivision of Pathology, Cancer Institute of Japanese Foundation for Cancer Research, Tokyo, Japan.
Ryohei KatohDepartment of Pathology, University of Yamanashi, Chuo, Yamanashi, Japan.
University of Yamanashi · JPJapanese Foundation For Cancer Research · JPIto Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thyroid papillary carcinoma is the most common endocrine neoplasm and generally carries a favorable prognosis. However, a small subset of papillary carcinomas transforms into anaplastic carcinoma, an undifferentiated cancer with a dismal prognosis. Recent studies using next-generation sequencing revealed the genomic landscape of papillary carcinoma and anaplastic carcinoma. However, risk factors for anaplastic transformation in papillary carcinoma remain obscure. In the present study, we investigated molecular alterations of papillary carcinoma and anaplastic carcinoma components in 27 tumors in which anaplastic carcinoma coexisted with antecedent papillary carcinoma. We conducted direct sequencing for BRAF, TERT promoter and PIK3CA, and immunohistochemistry for p53, TTF-1 and subunits of the SWI/SNF complex (ARID1A, ARID1B, ATRX, SMARCA2, SMARCA4, SMARCB1, and PBRM1). BRAF

Indexed as

AgedAged, 80 and overCarcinomaCarcinoma, PapillaryCell Transformation, NeoplasticFemaleHumansMaleMiddle AgedMutationRisk FactorsTelomeraseThyroid Cancer, PapillaryThyroid NeoplasmsTelomeraseTERT protein, human

Identifiers

PMID28731042
OpenAlexW2737662446

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.